• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

National Cancer Institute to back research efforts for local delivery of chemo

August 3, 2017 By Sarah Faulkner

National Cancer InstituteThe National Cancer Institute and the National Institutes of Health said last month that it plans to fund up to five projects involving novel methods to locally deliver chemopreventative drugs.

The two organizations pointed out that new technologies have enabled healthcare practitioners to detect cancer earlier in humans, but the ability to treat these high-risk patients is still limited due to the toxic side effects of chemopreventative agents.

Previous work has demonstrated that people with a high risk of developing cancer would benefit from the long-term administration of chemopreventative agents. And a small number of these drugs have seen success in the clinic – like tamoxifen and raloxifene for the prevention of breast cancer, according to the NCI.

“However, the systemic toxicities of these agents have limited their widespread use and acceptability,” the organization wrote.

“A localized chemoprevention approach is ideal in high risk individuals or individuals with premalignant diseases, as the agent can be applied locally to provide high drug concentrations at specific locations from where early disease would originate, while limiting systemic toxicity.”

The organization said it is looking for technologies that are designed for the effective delivery of a drug to a specific organ and that acceptable toxicities will vary depending on the agent and patient population.

The NCI noted that for novel chemoprevention agents, the proposal must prove that the drug significantly reduces cancer incidence in a suitable animal model. They also said that it would not fund a project that’s beyond a Phase II clinical trial.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: National Institutes of Health

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS